Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 7,883 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrates Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Eating Almonds Before a Meal to Control Blood Sugar

NCT07603739
View directory record Official record
Conditions
Glucose Control, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Precision Medicine, Nutrition
Interventions
Premeal almond ingestion
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
25 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Varenicline in Methadone-Stabilized Cocaine Users

NCT00567320
View directory record Official record
Conditions
Cocaine Dependence, Nicotine Dependence
Interventions
Varenicline, Sugar pill or Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

NCT01590888
View directory record Official record
Conditions
Huntington Disease
Interventions
PBT2, Placebo
Drug
Lead sponsor
Prana Biotechnology Limited
Industry
Eligibility
25 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
San Diego, California • Englewood, Colorado • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 19, 2026, 5:46 AM EDT
Withdrawn Phase 2 Interventional

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

NCT00006261
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic allogeneic lymphocytes, cyclophosphamide, docetaxel, doxorubicin hydrochloride, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

NCT03651622
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Overweight and Obesity
Interventions
Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646
View directory record Official record
Conditions
Breast Cancer
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

NCT06112353
View directory record Official record
Conditions
Intestinal Disease
Interventions
Neostigmine Injectable Solution, Sugammadex injection
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

NCT05789537
View directory record Official record
Conditions
Hemophilia B with Inhibitor, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 19, 2026, 5:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

NCT00410423
View directory record Official record
Conditions
Relapsed Acute Leukemia, Refractory Acute Leukemia
Interventions
Bortezomib with mitoxantrone, etoposide and cytarabine, Bortezomib 1.0mg/m^2, Bortezomib 1.3mg/m^2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 19, 2026, 5:46 AM EDT
Active, not recruiting Phase 2 Interventional

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

NCT02106988
View directory record Official record
Conditions
Lymphoma
Interventions
Radiation Therapy, Dexamethasone, Etoposide phosphate, Ifosfamide, Mesna, Carboplatin
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gefitinib plus etoposide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 19, 2026, 5:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effective Analgesia During Routine Immunizations

NCT01368861
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Children's Hospital of The King's Daughters
Other
Eligibility
2 Months to 4 Months
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 19, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional

Idiopathic Anemia of Aging (IAA)

NCT00104169
View directory record Official record
Conditions
Anemia, Aging
Interventions
Epoetin Alfa
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
70 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2008 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder

NCT02069366
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rewarding Healthy Behaviors in Pregnancy and Postpartum

NCT05328622
View directory record Official record
Conditions
Pregnancy Related
Interventions
Aqueduct Contingency Management Platform
Behavioral
Lead sponsor
Transcendent International, LLC
Industry
Eligibility
18 Years to 52 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of an Adaptive Treatment for Weight Loss in People With Prediabetes

NCT04745572
View directory record Official record
Conditions
PreDiabetes, Obesity
Interventions
High Carbohydrate Diet, Reduced Carbohydrate Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 19, 2026, 5:46 AM EDT
Recruiting No phase listed Observational

Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury

NCT05670288
View directory record Official record
Conditions
Spinal Cord Injuries, Gut Microbiome
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

NCT00569673
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, pegfilgrastim, docetaxel, trabectedin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
37
States / cities
Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 19, 2026, 5:46 AM EDT
Terminated Phase 3 Interventional

Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock

NCT03828929
View directory record Official record
Conditions
Septic Shock
Interventions
Vitamin C, Normal saline
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT00258245
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Treatment and Natural History Study of Lymphomatoid Granulomatosis

NCT00001379
View directory record Official record
Conditions
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
Interventions
Interferon, Rituxan and EPOCH, Tumor biopsy, Bone marrow biopsy, Bone marrow aspirate, Lumber puncture, CT, Brain MRI, Echocardiogram, FDG-PET
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 19, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

NCT01404754
View directory record Official record
Conditions
Psychological Effects of Study Drug
Interventions
Lactose (inactive placebo), midomafetamine HCl
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
3
States / cities
Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 19, 2026, 5:46 AM EDT